Skip to content
Search

Latest Stories

Esperion Therapeutics’ ‘bempedoic acid’ shows potential to reduce cardiac illnesses, reveals GlobalData

Esperion Therapeutics’ non-statin therapy “bempedoic acid” has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company.

As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said GlobalData.


According to GlobalData’s Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025.

Neha Myneni, Pharma Analyst at GlobalData, comments: “Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses. However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space.”

Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins, niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).

CETPi inhibitors are example of a failed class of therapy for statin-intolerant patients. Till date, four CETPi inhibitors (Pfizer’s torcetrapib; Merck’s anacetrapib; Roche’s dalcetrapib; and Lilly’s evacetrapib) reached Phase III cardiovascular outcome trials. However, further development of all these molecules was discontinued due to their insufficient cardiovascular benefit for regular use.

Myneni concludes: “With a potential to address about 100,000–500,000 statin-intolerant patients in Australia, bempedoic acid, however, may not be considered an alternate to statin therapy at this juncture with only moderate improvement in LDL lowering efficacy and reduction in cardiovascular risk. Further trials comparing the efficacy of bempedoic acid head-on with statins or other established therapies in future could prove its efficacy in LDL treatment.”

More For You

GPhC should consider reduced fees for pharmacists non-practising practising, says RPS

RPS responds to GPhC consultation on draft changes to fees

gettyimages

RPS urges GPhC to reduce registration fees for non-practising pharmacists

The Royal Pharmaceutical Society (RPS) has called on the General Pharmaceutical Council (GPhC) to reduce annual registration fees for non-practising pharmacists — such as those on parental leave or with a long-term illness — in response to the regulator’s consultation on proposed changes to fees.

The GPhC is proposing a 6% increase in annual registration fees from September 2025 to cover the rising operational costs.

Keep ReadingShow less
Nick Kaye
Nick Kaye appointed as NPA's new chair
Nick Kaye appointed as NPA's new chair

Breaking news: NPA members advised against collective action

With the government’s recent announcement of increased funding to the sector signalling a ‘clear step forward’, the National Pharmacy Association (NPA) has today announced that it will not be recommending collective action to its members.

Last month, the department of health announced the Community Pharmacy Contractual Framework (CPCF) with an increase in funding for 2024/25 of £106m to £2.7 billion and simultaneously a further increase to £3.1 billion for 25/26.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
​Pope Francis

Pope Francis at the Vatican on December 4, 2024.

Photo by FILIPPO MONTEFORTE/AFP via Getty Images

His Holiness Mahant Swami Maharaj offers condolences to Catholic community following Pope Francis' passing

His Holiness Mahant Swami Maharaj, the spiritual leader and president of the Bochasanwasi Akshar Purushottam Swaminarayan Sanstha (BAPS), has expressed heartfelt condolences to the Catholic community worldwide following the passing of Pope Francis on Monday.

In a formal letter addressed to the members of the Roman Catholic Church, Mahant Swami Maharaj conveyed the deep sorrow of the BAPS Swaminarayan Hindu fellowship, acknowledging the Pope's passing as “a profound loss to the Catholic community and Christians around the world.”

Keep ReadingShow less